NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit
Lund, Sweden, January 19, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer data related to the company’s sanglifehrin-based compounds has been accepted for presentation at the scientific conference EASL HCC Summit to take place in Geneva, Switzerland, 2-5 February, 2017.NeuroVive has utilized its expertise in mitochondrial medicine to explore a unique aspect of the company’s sanglifehrin-based compounds.